Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
2.830
-0.060 (-2.08%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
$328,000
Profits / Employee
-$293,581
Market Cap
202.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 146 |
| Arcturus Therapeutics Holdings | 111 |
| Nkarta | 108 |
| Alector | 103 |
| Immunic | 95 |
| Camp4 Therapeutics | 48 |
| Q32 Bio | 22 |
| Outlook Therapeutics | 17 |
CLLS News
- 2 days ago - Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - GlobeNewsWire
- 17 days ago - Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewsWire
- 17 days ago - Cellectis Slides: FY 2026 - Filings
- 18 days ago - Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise - GuruFocus
- 18 days ago - Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy - GuruFocus
- 18 days ago - Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA - TheFly
- 18 days ago - Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL - GlobeNewsWire
- 24 days ago - Monthly information on share capital and company voting rights - GlobeNewsWire